Accelitech announces new CyberKnife Cancer Institute of Chicago

NewsGuard 100/100 Score

Accelitech LLC, a leading developer of stereotactic radiosurgery and cancer treatment programs, is pleased to announce its newest CyberKnife cancer center, which will begin treating patients in Chicago in the summer of 2012. Developed through a partnership between Accelitech, physicians and Swedish Covenant Hospital, the new CyberKnife Cancer Institute of Chicago will provide state-of-the-art CyberKnife treatment to patients from Chicago and beyond. This will be the first CyberKnife center within the city limits and will feature the latest technology of its kind in the region.

Centrally located and conveniently accessible from both downtown and suburban locations, the new 10,000-square-foot facility, now under construction, will be located at 160 East Illinois, in the heart of Chicago. The center will open and the clinical team will begin evaluating patients for treatment beginning this spring.

"Our vision is to create the very best setting for patient care and provide the most advanced cancer treatment technology available in the market," says Adam Dickler, MD, the Medical Director for the new CyberKnife center. "More than 20 cancer care physicians have been trained to use the CyberKnife, providing new treatment options for their patients."

"With this and every project, our goal is to bring new technology to patients who need it most, so we're very excited to add our Chicago site to a rapidly growing network of Accelitech CyberKnife centers," says Kerwin Brandt, CEO of Accelitech. "With nine existing locations and many more under development, we believe we are the largest and fastest growing private developer of CyberKnife centers in the country."

Source:

Accelitech LLC

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aspirin's immune-boosting effects in colorectal cancer revealed